Gamida Cell Ltd. (GMDA) Tops Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pre-Open Stock Movers 05/19: (ABUS) (DVAX) (AAP) Higher; (BLPH) (GMDA) (GOOS) Lower (more...)
May 19, 2020 9:30 AM EDTPre-Open Stock Movers:
Arbutus Biopharma Corporation (Nasdaq: ABUS) 42.2% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.
Dynavax (Nasdaq: DVAX) 40.3% HIGHER; intends to provide an update on its early-stage collaborations regarding the potential development of a vaccine for COVID-19
Bellerophon Therapeutics, Inc. (Nasdaq:... More
Gamida Cell Ltd. (GMDA) Prices 13.334M Share Common Offering at $4.50/Sh
May 19, 2020 5:48 AM EDTGamida Cell Ltd. (NASDAQ: GMDA) today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition,... More
